gp100(209-217)

gp100(209-217) is a synthetic peptide fragment derived from the human glycoprotein 100 (gp100), a melanocyte differentiation antigen that is highly relevant in melanoma research. Composed of nine amino acids corresponding to residues 209 through 217 of the parent protein, this peptide serves as a well-characterized epitope recognized by cytotoxic T lymphocytes (CTLs) in the context of major histocompatibility complex (MHC) class I molecules. Its defined sequence and immunogenic properties make it a valuable molecular tool for studies focused on antigen processing, immune recognition, and T cell activation within the field of tumor immunology and cellular immunotherapy research.

Immunological Assays: gp100(209-217) is extensively utilized in immunological assays designed to investigate antigen-specific T cell responses. Researchers employ this peptide in enzyme-linked immunospot (ELISPOT) assays, intracellular cytokine staining, and tetramer staining to quantify and characterize gp100-specific CTL populations. By presenting the peptide to peripheral blood mononuclear cells (PBMCs) or isolated T cell subsets, investigators can assess the frequency, phenotype, and functional profile of antigen-reactive T cells, providing critical insights into immune surveillance mechanisms and the development of anti-tumor immunity.

Antigen Presentation Studies: The peptide serves as a robust model antigen for dissecting the molecular mechanisms underlying MHC class I antigen processing and presentation. By pulsing antigen-presenting cells (APCs) such as dendritic cells or B cells with gp100(209-217), researchers can evaluate peptide loading efficiency, stability of peptide-MHC complexes, and the subsequent activation of CD8+ T cells. These studies are instrumental in elucidating the pathways that govern cellular immune recognition and inform the optimization of peptide-based vaccine strategies.

T Cell Activation and Functional Analysis: In vitro stimulation of T cells with gp100(209-217) enables detailed analysis of antigen-specific activation, proliferation, and effector function. The peptide is frequently used to prime or restimulate CTLs in culture, allowing for the assessment of cytokine production, cytotoxicity, and memory formation. These functional assays contribute to the understanding of T cell-mediated cytolytic activity against melanoma cells and facilitate the identification of correlates of protective immunity in experimental models.

Peptide-Based Vaccine Development: As a well-defined melanoma-associated epitope, gp100(209-217) is integral to preclinical research on peptide-based vaccine formulations. It is incorporated into vaccine prototypes to evaluate immunogenicity, dose optimization, and adjuvant effects in animal models or ex vivo human systems. Such studies inform the rational design of immunotherapeutic approaches aimed at enhancing anti-tumor responses by targeting tumor-associated antigens with high specificity.

Quality Control and Standardization: The high sequence fidelity and defined immunological properties of gp100(209-217) make it an ideal reference material for assay calibration and method validation. Laboratories engaged in immunomonitoring or vaccine research use this peptide as a positive control to ensure assay reproducibility, sensitivity, and specificity. Its application in quality assurance protocols supports the generation of reliable and interpretable data across diverse experimental platforms, contributing to the standardization of immunological assays in cancer research.

1. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

2. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

3. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry